Allendale Pharma's Today Sponge Labeling Passes FDA Panel Muster
This article was originally published in The Gray Sheet
Executive Summary
Proposed labeling for Allendale Pharmaceuticals' Today sponge adequately conveys the risks associated with use of the female contraceptive albeit with some minor adjustments, FDA's Nonprescription Drugs Advisory Committee concluded at a July 12 meeting.
You may also be interested in...
Spongeworthy
Allendale Pharmaceuticals recommences sales of the Today Sponge via two Canadian Internet sites. FDA approval is expected within a year after being off the market since 1995 due to quality control systems issues (1"The Gray Sheet" July 17, 2000, p. 11)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”